Selected press releases

The start-up xenko has been awarded an EXIST grant of 143,500 € from the Federal Ministry for Economic Affairs and Energy. The team of founders from Ulm University is developing a digital health platform designed to encourage more physical activity in everyday working life through virtual reality. This development is of interest to companies with occupational health management schemes and, in the long term, to the physiotherapy sector as well.

An international consortium led by researchers at the Heidelberg Faculty of Medicine at Heidelberg University will develop an AI-powered interactive assistant for the analysis of patient experiences over the next four years. The goal is to identify individual burdens and challenges early and comprehensively and make this information actionable for patients, care teams, and health systems.

A project funded by the Baden-Württemberg Stiftung at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg is investigating the interplay between RNA modifications and epigenetic mechanisms during cell division – and its potential significance for treatment resistance in cancer.

With clinical medicine and medical technology Heidelberg University is again among the best players in Medical Sciences worldwide. In the Global Ranking of Academic Subjects 2026 clinical medicine rose by one place over last year to rank 17th internationally in clinical medicine and so leads the field in Germany. Medical technology is in 21st place internationally and continues to be ranked third in Germany.

Thanks to enzyme-based biocatalysis, an enormous range of pharmaceutical active ingredients and other complex molecules can be synthesized in an environmentally friendly manner. Researchers at the Karlsruhe Institute of Technology (KIT) have now developed a technology that allows to assemble enzymes into millimeter-sized, storable beads. In this process, the enzymes not only act as catalysts but also constitute the beads’ material itself.

ViferaXS, a clinical-stage biotechnology company developing peptide-based cancer immunotherapy for hematologic malignancies and solid tumors, today announced the close of the Series A financing round of up to €12 million, including grant funding. The round was led by SPRIND, the German Federal Agency for Breakthrough Innovation, and Huma, with participation from private investors.

A team of researchers at the University of Stuttgart has developed a new method that could make MRI even more precise by eliminating “dead time,” a key limiting factor in the measurement process, thereby enabling the detection of signals that are lost using conventional methods. This method opens up new possibilities for medical diagnostics and non-destructive materials testing. The research team presents the new approach in Science Advances.

Effective 1 October 2026, Professor Jakob Nikolas Kather will assume the Hopp Foundation Professorship for “Artificial Intelligence in Medicine” at the Heidelberg Faculty of Medicine at Heidelberg University. Associated with the professorship is the establishment of the new Institute for Medical AI (IMAI) at Heidelberg University Hospital, which Professor Kather will lead as its founding director.

Prof. Chunhai Fan, who is a recipient of the Humboldt Research Award, has been conducting research at the University of Stuttgart since June. Fan works closely with Prof. Laura Na Liu of the 2nd Physics Institute. Both researchers are among the world's leading experts in the field of DNA nanotechnology.

While the cell nucleus contains almost all of the genome, the mitochondria – the powerhouses of the cell – have their own small genetic code. It consists of only 37 genes, which are organized in circular DNA – mtDNA, for short. Defects in the mitochondrial genome are related to incurable neurodegenerative and metabolic diseases, cancer and also aging processes.

CAR T-cell therapies are used successfully to treat certain blood cancers. However, while some patients respond even to low-dose treatment, others derive no benefit. Researchers from the Heidelberg Faculty of Medicine at Heidelberg University and the Berlin Institute of Health at Charité (BIH) investigated the reasons behind these differences in a collaborative research project.

With funding from the German Research Foundation’s (DFG) Heisenberg Program, DKFZ researcher Aurélie Ernst aims to investigate how massive changes in the genome contribute to the development of cancer. Her research focuses on a phenomenon known as chromothripsis - a catastrophic event in the genome in which chromosomes break apart and are reassembled incorrectly.